Literature DB >> 17957847

Markers of chemoradiation resistance in patients with locally advanced head and neck squamous cell carcinoma, treated by intra-arterial carboplatin and concurrent radiation.

L Mannarini1, G Bertino, P Morbini, C Villa, M Benazzo.   

Abstract

The onset of chemo- and/or radio-resistance in tumour cells is one of the main causes of failure of integrated treatment protocols combining intra-arterial administration of platinum derivatives and radiotherapy, and is associated with recurrent disease and/or distant metastases. In the present study, the expression of a series of markers of chemo- and/or radio-resistance was investigated in 21 patients with advanced squamous cell carcinoma of the head and neck treated with combined intra-arterial carboplatin and radiotherapy. The results were correlated with local response to treatment, recurrence and overall and disease-free survival. In non-responders or in patients presenting recurrence, caspase 8 was significantly (p 0.05) under-expressed while p-Gp (p 0.035) and MDR-3 (p 0.049) were significantly over-expressed. Tumours with unfavourable outcome more frequently over-expressed two or more anti-apoptotic factors (p-53, BCL-2, BCL-x) (p 0.01). Patients with shorter overall survival, significantly overexpressed p53 (p 0.04), LRP (p 0.038) and a larger number of trans-membrane transport proteins compared with those who survived more than one year (p 0.013). Finally, patients with the shortest disease-free survival presented over-expression of p53 (p 0.027) and BCL-x (p 0.023). Further studies are necessary to confirm the possibility, in a future perspective, of using a panel of markers of chemo- and radio-resistance to identify those patients potentially sensitive to the treatment and to avoid patients at high risk of resistance from being submitted to ineffective and toxic treatment protocols.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17957847      PMCID: PMC2640025     

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Ital        ISSN: 0392-100X            Impact factor:   2.124


  37 in total

Review 1.  The MRP family of drug efflux pumps.

Authors:  Gary D Kruh; Martin G Belinsky
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

Review 2.  Genealogy, expression, and molecular mechanisms in apoptosis.

Authors:  Zodwa Dlamini; Zukile Mbita; Makhosazana Zungu
Journal:  Pharmacol Ther       Date:  2004-01       Impact factor: 12.310

Review 3.  Genetic predisposition to colorectal cancer.

Authors:  Albert de la Chapelle
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

Review 4.  A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence.

Authors:  M Sawicka; M Kalinowska; J Skierski; W Lewandowski
Journal:  J Pharm Pharmacol       Date:  2004-09       Impact factor: 3.765

5.  Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study.

Authors:  Annemarie Larkin; Lorraine O'Driscoll; Susan Kennedy; Rachel Purcell; Elizabeth Moran; John Crown; Michael Parkinson; Martin Clynes
Journal:  Int J Cancer       Date:  2004-11-01       Impact factor: 7.396

6.  Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy.

Authors:  Francesca M Buffa; Søren M Bentzen; Frances M Daley; Stanley Dische; Michele I Saunders; Paul I Richman; George D Wilson
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

7.  Imbalance between proliferation and apoptosis may be responsible for treatment failure after postoperative radiotherapy in squamous cell carcinoma of the oropharynx.

Authors:  Gerhard G Grabenbauer; Olga Suckorada; Gerald Niedobitek; Franz Rödel; Heiner Iro; Rolf Sauer; Claus Rödel; Stefan Schultze-Mosgau; Luitpold Distel
Journal:  Oral Oncol       Date:  2003-07       Impact factor: 5.337

8.  p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma.

Authors:  R Jayasurya; Geo Francis; S Kannan; K Lekshminarayanan; K R Nalinakumari; Thomas Abraham; Elizabeth K Abraham; M Krishnan Nair
Journal:  Int J Cancer       Date:  2004-05-01       Impact factor: 7.396

Review 9.  Apoptosis pathways in cancer and cancer therapy.

Authors:  Klaus-Michael Debatin
Journal:  Cancer Immunol Immunother       Date:  2004-01-29       Impact factor: 6.968

10.  Allelic imbalance at the DNA mismatch repair loci, hMSH2, hMLH1, hPMS1, hPMS2 and hMSH3, in squamous cell carcinoma of the head and neck.

Authors:  J Nunn; S Nagini; J M Risk; W Prime; P Maloney; T Liloglou; A S Jones; S R Rogers; J R Gosney; J Woolgar; J K Field
Journal:  Oral Oncol       Date:  2003-02       Impact factor: 5.337

View more
  3 in total

1.  PITX1 is a novel predictor of the response to chemotherapy in head and neck squamous cell carcinoma.

Authors:  Masao Takenobu; Mitsuhiko Osaki; Kazunori Fujiwara; Takahiro Fukuhara; Hiroya Kitano; Hiroyuki Kugoh; Futoshi Okada
Journal:  Mol Clin Oncol       Date:  2016-04-28

2.  Multidrug-resistance proteins are weak tumor associated antigens for colorectal carcinoma.

Authors:  Christina S Mullins; Sven Eisold; Ernst Klar; Michael Linnebacher
Journal:  BMC Immunol       Date:  2011-07-10       Impact factor: 3.615

3.  P53 nuclear stabilization is associated with FHIT loss and younger age of onset in squamous cell carcinoma of oral tongue.

Authors:  Raju Adduri; Viswakalyan Kotapalli; Neha A Gupta; Swarnalata Gowrishankar; Mukta Srinivasulu; Mohammed Mujtaba Ali; Subramanyeshwar Rao; Shantveer G Uppin; Umanath K Nayak; Snehalatha Dhagam; Mohana Vamsy Chigurupati; Murali Dharan Bashyam
Journal:  BMC Clin Pathol       Date:  2014-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.